自然杀伤细胞/T细胞淋巴瘤的靶向治疗研究进展  

Research progress of targeted therapy of NK/T cell lymphoma

作　　者：吴晓鸿[1] 谭获[1] 

机构地区：[1]广州医科大学附属第一医院肿瘤血液科,510230

出　　处：《国际输血及血液学杂志》2015年第2期132-135,共4页International Journal of Blood Transfusion and Hematology

基　　金：广东省临床重点专科基金资助项目（20111219）

摘　　要：自然杀伤细胞/T细胞（NK/T细胞）淋巴瘤是一种起源于自然杀伤（NK）细胞的,具有高度侵袭性的非霍奇金淋巴瘤,多累及结外器官,因其独特的免疫表型而被命名.该病发生具有明显的地域性,发病机制目前仍未阐明,大部分研究表明其与Epstein-Barr（EB）病毒相关.对于NK/T细胞淋巴瘤的治疗,目前尚无标准治疗方案,临床多采用放、化疗结合方案治疗,而各种新型靶向治疗药物也为目前的研究热点.笔者拟从信号传导通路及EB病毒相关机制方面,对NK/T细胞淋巴瘤靶向治疗进行综述.Natural killer cells/T cell （NK/T cell） lymphoma originates from NK cells and it is a kind of highly invasive non-hodgkin＆#39;s lymphoma which has a predilection for extranodal organs.It is named for its unique immune phenotype and its distribution has regional character.However,its pathogenesis is still not clarified.Many researches show that NK/T cell lymphoma relates with Epstein-Barr （EB） virus.So far,there is no standard treatment guideline for NK/T cell lymphoma.Clinically,the treatment of NK/T cell lymphoma involves chemoradiotherapy.Fortunately,its new targeted therapy is becoming a hot research topic.And this article will make a review at signaling pathways and EB virus mechanisms of NK/T cell lymphoma in targeted therapy.

关 键 词：淋巴瘤 结外NK-T细胞 信号传导 EPSTEIN-BARR病毒 分子靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]